Recap: Zynex Q3 Earnings

Shares of Zynex ZYXI decreased 2.79% in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share fell 33.33% year over year to $0.04, which missed the estimate of $0.05.

Revenue of $20,026,000 up by 69.47% from the same period last year, which missed the estimate of $21,130,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

The upcoming fiscal year's revenue expected to be between $80,000,000 and $81,000,000.

Details Of The Call

Date: Oct 27, 2020

Time: 04:15 PM

ET Webcast URL: https://www.webcaster4.com/Webcast/Page/1487/38303

Price Action

52-week high: $29.73

52-week low: $7.51

Price action over last quarter: down 25.26%

Company Profile

Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufacture, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. it also develops and markets medical devices for non-invasive cardiac monitoring, the products of which are under development. The company markets Zynex-manufactured products which include NexWave, NeuroMove, InWave, Non-Invasive Blood Volume Monitor and others.